10-Q: FutureTech II Acquisition Corp. Reports Net Loss for Q3 2024, Faces Nasdaq Delisting Concerns Amid Business Combination Efforts

FutureTech II Acquisition Corp. reports a net loss for Q3 2024 and is working to complete a business combination with Longevity Biomedical, Inc. while addressing Nasdaq compliance issues.

Summary

• FutureTech II Acquisition Corp. reported a net loss of $123,127 for the three months ended September 30, 2024, and a net loss of $38,005 for the nine months ended September 30, 2024.
• The company's expenses were $367,118 for the quarter and $962,945 for the nine-month period.
• Interest income from the Trust Account was $287,584 for the quarter and $1,107,012 for the nine-month period.
• The company is pursuing a business combination with Longevity Biomedical, Inc., announced on September 16, 2024.
• FutureTech II is working to regain compliance with Nasdaq listing requirements, including minimum Market Value of Listed Securities and Publicly Held Shares.
• The company received a notice from Nasdaq regarding non-compliance with listing rules and has appealed the Staff's Determination.
• The company has extended the period to complete a business combination to August 18, 2025, through stockholder approval and sponsor contributions.
• There was an overpayment in the redemption of shares in connection with the First and Second Extension Meetings, and the company is working to recover these amounts.
• The company's management has identified a material weakness in internal control over financial reporting related to the accounting of extension loans and the calculation of the redemption price.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the net loss, working capital deficit, Nasdaq compliance issues, and material weakness in internal control. While the company is pursuing a business combination, the challenges and risks outweigh the potential positives.

Positives

• The company is actively pursuing a business combination with Longevity Biomedical, Inc.
• The company has secured an extension to complete the business combination until August 18, 2025.
• The company is taking steps to address Nasdaq compliance issues and maintain its listing.
• The company is working to recover overpayment amounts from redeeming shareholders.

Negatives

• The company reported a net loss for the three and nine months ended September 30, 2024.
• The company has a significant working capital deficit.
• The company is facing potential delisting from Nasdaq due to non-compliance with listing rules.
• The company identified a material weakness in internal control over financial reporting.
• There was an overpayment in the redemption of shares in connection with the First and Second Extension Meetings.

Risks

• The company may not be able to complete the business combination with Longevity Biomedical, Inc.
• The company may not be able to regain compliance with Nasdaq listing requirements and could be delisted.
• The company's financial condition raises substantial doubt about its ability to continue as a going concern.
• The company's internal control over financial reporting is not effective.
• The company is subject to risks related to the COVID-19 pandemic, the conflict in Ukraine, and the conflict in the Middle East.
• The company is subject to a new excise tax on stock buybacks.

Future Outlook

The company is focused on completing its business combination with Longevity Biomedical, Inc. and regaining compliance with Nasdaq listing requirements. The company has until August 18, 2025, to complete a business combination.

Industry Context

The report reflects the challenges faced by many SPACs in the current market, including difficulties in completing business combinations and maintaining listing compliance. The company's efforts to extend its timeline and secure additional funding are common strategies in the SPAC industry.

Comparison to Industry Standards

• Given the current market conditions, FutureTech II's situation is not unique, as many SPACs are struggling to find suitable targets and maintain listing requirements.
• Compared to other SPACs, the company's cash position and working capital deficit are concerning, highlighting the need for additional funding.
• The company's efforts to extend its timeline and secure additional funding are similar to strategies employed by other SPACs facing similar challenges.
• The material weakness in internal control over financial reporting is a significant concern and needs to be addressed promptly to restore investor confidence.

Related Party Transactions

• The Sponsor has provided Extension Loans to the company to extend the period to complete a business combination.
• The company has an administrative support agreement with the Sponsor.
• The company has paid expenses that will be reimbursed by the Sponsor.

Stakeholder Impact

• Shareholders are impacted by the potential delisting from Nasdaq and the company's financial condition.
• Shareholders are impacted by the overpayment in the redemption of shares.
• The company's employees and management are impacted by the challenges in completing a business combination and maintaining listing compliance.
• The company's creditors and suppliers are impacted by the company's financial condition and ability to continue as a going concern.

Next Steps

• Complete the business combination with Longevity Biomedical, Inc.
• Regain compliance with Nasdaq listing requirements.
• Remediate the material weakness in internal control over financial reporting.
• Recover overpayment amounts from redeeming shareholders.
• File the delayed Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 with the SEC.

Key Dates